Canopy Growth (WEED) Stock Overview
Engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
WEED Community Fair Values
Create NarrativeSee what 46 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ST
stuart_roberts
Community ContributorUS$21.53FV • 64.4% undervalued intrinsic discount
5419.8%Revenue growth p.a.
6.2k
18
0
126
Canopy Growth Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.51 |
| 52 Week High | CA$3.28 |
| 52 Week Low | CA$1.18 |
| Beta | 2.32 |
| 1 Month Change | 14.39% |
| 3 Month Change | 0.67% |
| 1 Year Change | -22.16% |
| 3 Year Change | -91.01% |
| 5 Year Change | -99.49% |
| Change since IPO | -94.17% |
Recent News & Updates
WEED: New Brand Launch And Equity Raise Will Support Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth from CA$5.00 to CA$4.82, citing updated assumptions that include a slightly lower revenue growth outlook, a higher profit margin and a reduced future P/E multiple. What's in the News Canopy Growth launched Deelish, a new cannabis brand aimed at everyday consumers, with products positioned at everyday price points and high THC content across both flower and pre-roll formats (Key Developments).
WEED: Everyday Brand Launch And Equity Raise Will Support Future Upside
Analysts have adjusted their CA$ price target on Canopy Growth to reflect updated views on long term revenue growth, profit margin assumptions, and a lower projected future P/E multiple. This has resulted in a slightly different outlook than before.WEED: Term Loan Refinancing Will Support Medical Expansion And New Formats
Analysts have reduced their Canopy Growth fair value estimate from CA$3.20 to about CA$2.38, citing updated assumptions around revenue growth, profit margins, the discount rate, and a lower expected future P/E multiple. What's in the News Canopy Growth filed a follow-on equity offering of approximately $19.27 million, covering 18,705,578 common shares priced at $1.03 each (Key Developments).Recent updates
WEED: New Brand Launch And Equity Raise Will Support Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth from CA$5.00 to CA$4.82, citing updated assumptions that include a slightly lower revenue growth outlook, a higher profit margin and a reduced future P/E multiple. What's in the News Canopy Growth launched Deelish, a new cannabis brand aimed at everyday consumers, with products positioned at everyday price points and high THC content across both flower and pre-roll formats (Key Developments).WEED: Everyday Brand Launch And Equity Raise Will Support Future Upside
Analysts have adjusted their CA$ price target on Canopy Growth to reflect updated views on long term revenue growth, profit margin assumptions, and a lower projected future P/E multiple. This has resulted in a slightly different outlook than before.WEED: Term Loan Refinancing Will Support Medical Expansion And New Formats
Analysts have reduced their Canopy Growth fair value estimate from CA$3.20 to about CA$2.38, citing updated assumptions around revenue growth, profit margins, the discount rate, and a lower expected future P/E multiple. What's in the News Canopy Growth filed a follow-on equity offering of approximately $19.27 million, covering 18,705,578 common shares priced at $1.03 each (Key Developments).WEED: Term Loan And Equity Raise Will Support Future Acquisitions
Analysts have trimmed their CA$ price target on Canopy Growth, citing slightly higher projected revenue growth, a lower profit margin outlook, and a higher assumed future P/E multiple. Together, these factors imply a more cautious stance on the shares.WEED: Term Loan And Equity Raise Will Support Future Portfolio Expansion
Analysts have adjusted their price target on Canopy Growth to CA$5.00, reflecting updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple. What's in the News Filed a follow-on equity offering of approximately $19.27 million, covering 18,705,578 common shares priced at about $1.03 per share (Key Developments).WEED: Term Loan Funding Will Support Expansion Of Medical And Adult-Use Portfolio
Analysts have trimmed their fair value estimate for Canopy Growth from $8.00 to $5.00, citing higher assumed revenue growth of 14.73% paired with much thinner profit margins of 4.78% and a very large 137.82x future P/E, which together point to a riskier and more expensive earnings profile. What's in the News Canopy Growth entered a term loan agreement to receive net proceeds of US$150 million from lenders led by JGB Management Inc., with the loan maturing in January 2031.WEED: Medical Expansion And New Product Formats Will Drive Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth from US$3.76 to about US$3.20. This reflects updated assumptions around slower revenue growth, a slightly lower future P/E, and a broadly unchanged margin and discount rate profile.More Unpleasant Surprises Could Be In Store For Canopy Growth Corporation's (TSE:WEED) Shares After Tumbling 28%
Jan 11
WEED: Medical And Adult Use Product Expansion Will Drive Future Upside
Analysts have made only very small tweaks to their inputs for Canopy Growth, keeping the fair value estimate steady at $3.76 while slightly adjusting assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these changes support a largely unchanged price target outlook.WEED: Medical Expansion Will Drive Future Upside For Shares
Analysts have nudged their price target on Canopy Growth higher to reflect an improved fair value estimate, rising from approximately $3.30 to $3.76. This revision is supported by slightly stronger projected revenue growth, a notable uplift in expected profit margins, and a lower anticipated future price to earnings multiple.WEED: Medical Expansion And Share Consolidation Will Drive Future Upside
Analysts have modestly adjusted their price target on Canopy Growth, citing largely unchanged assumptions for fair value at approximately 3.30 dollars, a stable discount rate near 6.12 percent, and essentially flat outlooks for revenue growth, profit margins, and future valuation multiples. What's in the News Launched Claybourne Gassers All in One vapes featuring high potency liquid diamonds and anti clog, anti burn technology, along with new Claybourne Frosted Flyers infused pre roll variety packs in select Canadian regions and online medical channels (Key Developments) Expanded the Spectrum Therapeutics portfolio in Australia with new CBD, THC, and balanced softgel capsules, deepening the company’s presence in the maturing Australian medical cannabis market (Key Developments) Shareholders approved amendments to the company’s articles to allow a potential consolidation of common and exchangeable shares, giving the board discretionary authority to implement a reverse split within 12 months (Key Developments) Transitioned the DOJA facility in Kelowna, British Columbia, into an exclusive medical cultivation site under a micro cultivation license, focused on small batch craft cannabis for Spectrum Therapeutics patients, including veterans (Key Developments) Appointed Tom Stewart as permanent Chief Financial Officer, formalizing his role after serving as interim CFO and leading efforts to stabilize the balance sheet, cut expenses, and improve liquidity (Key Developments) Valuation Changes Fair Value: Unchanged at approximately CA$3.30 per share, indicating no material revision to intrinsic value estimates.WEED: Improving Profit Margins And Share Consolidation Will Drive Future Upside
Analysts have raised their price target for Canopy Growth from $1.30 to $3.30. They cite improvements in profit margin projections and expectations of sustained profitability, despite moderated revenue growth forecasts.Canopy Growth Corporation's (TSE:WEED) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Nov 15Canopy Growth Corporation (TSE:WEED) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Nov 10WEED: Rising Discount Rate Will Pressure Share Price In The Months Ahead
Analysts have adjusted their price target for Canopy Growth downward from $2.64 to $1.30. They cited an increased discount rate as well as ongoing evaluations of profit margin and future earnings potential.Revenues Tell The Story For Canopy Growth Corporation (TSE:WEED) As Its Stock Soars 70%
Aug 30European Expansion And Operational Improvements Will Unlock Cannabis Potential
Consensus analyst price targets for Canopy Growth have been revised lower primarily due to a marked slowdown in forecast revenue growth, resulting in a fair value decrease from CA$3.31 to CA$2.98. What's in the News Canopy Growth introduced its Canadian-grown 7ACRES brand in Australia, expanding its medical cannabis portfolio with high-THC sativa strains Ultra Jack and Jack Frost.Investors Appear Satisfied With Canopy Growth Corporation's (TSE:WEED) Prospects As Shares Rocket 40%
May 18What You Can Learn From Canopy Growth Corporation's (TSE:WEED) P/S After Its 28% Share Price Crash
Apr 02
New Medical Cannabis And Vaporizer Offerings Will Expand Global Markets
Growth in the medical cannabis sector and product innovation in adult-use and premium vaporizers position Canopy for revenue and market share expansion.Canopy Growth Corporation's (TSE:WEED) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Feb 12Canopy Growth Corporation's (TSE:WEED) Popularity With Investors Under Threat As Stock Sinks 26%
Dec 22Canopy Growth Corporation (TSE:WEED) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Nov 05More Unpleasant Surprises Could Be In Store For Canopy Growth Corporation's (TSE:WEED) Shares After Tumbling 26%
Aug 28We Think Canopy Growth (TSE:WEED) Has A Fair Chunk Of Debt
Aug 17Some Confidence Is Lacking In Canopy Growth Corporation (TSE:WEED) As Shares Slide 26%
Jun 15Shareholder Returns
| WEED | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -8.5% | 11.5% | 0.3% |
| 1Y | -22.2% | 46.0% | 36.6% |
Return vs Industry: WEED underperformed the Canadian Pharmaceuticals industry which returned 38.9% over the past year.
Return vs Market: WEED underperformed the Canadian Market which returned 33.8% over the past year.
Price Volatility
| WEED volatility | |
|---|---|
| WEED Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 10.6% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 4.0% |
Stable Share Price: WEED has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: WEED's weekly volatility has decreased from 16% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 960 | Luc Mongeau | www.canopygrowth.com |
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such as softgel capsules; cannabis edibles, including gummies; cannabis vapes; and oils, beverages, concentrates.
Canopy Growth Corporation Fundamentals Summary
| WEED fundamental statistics | |
|---|---|
| Market cap | CA$571.23m |
| Earnings (TTM) | -CA$327.29m |
| Revenue (TTM) | CA$278.39m |
2.1x
P/S Ratio-1.8x
P/E RatioIs WEED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WEED income statement (TTM) | |
|---|---|
| Revenue | CA$278.39m |
| Cost of Revenue | CA$204.45m |
| Gross Profit | CA$73.94m |
| Other Expenses | CA$401.24m |
| Earnings | -CA$327.29m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.86 |
| Gross Margin | 26.56% |
| Net Profit Margin | -117.57% |
| Debt/Equity Ratio | 29.7% |
How did WEED perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 05:43 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Canopy Growth Corporation is covered by 23 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |